document.addEventListener("click", function (e) {
    if (e.target.classList == "button next") {
        setTimeout(function () {
            document.querySelector("#content-end").innerHTML = '<p>Try another patient scenario</p><label for="allergicStatus">Allergic Status</label><select name="allergicStatus" id="allergicStatus"><option value="" disabled selected>Select Status</option><option value="allergic-option1">Allergic to perennial allergen (positive allergy test)</option><option value="allergic-option2">Non-allergic to perennial allergen (negative allergy test)</option><option value="allergic-option3">Unknown</option></select><label for="bloodEosinophilCount">Blood Eosinophil Count</label><select name="bloodEosinophilCount" id="bloodEosinophilCount"><option value="" disabled selected>Select BEC</option><option value="bec-option1">&#60;150</option><option value="bec-option2">150-299</option><option value="bec-option3">300-499</option><option value="bec-option4">&#8805;450</option><option value="bec-option5">Unknown</option></select><button class="re-calculate" id="re-calculate-id">Recalculate</button>';
        }, 3000);
    }
    if (e.target.id == "re-calculate-id") {

        var lcOrigin = document.referrer;
        const obj = {
            allergicStatus: document.getElementById("allergicStatus").value,
            bloodEosinophilCount: document.getElementById("bloodEosinophilCount").value
        };
        window.top.postMessage(JSON.stringify(obj), lcOrigin);
        // Get the values of allergicStatus and bloodEosinophilCount from the selects
        var allergicStatus = document.getElementById("allergicStatus").value;
        var bloodEosinophilCount = document.getElementById("bloodEosinophilCount").value;

        var outcome1 = '<div class="topContainer">    <div class="results-section">        <p class="response-title-section">In patients with:</p>        <li class="resTitleDetails"><span sa-data-type="custom_variable">Positive allergic status </span></li>        <li class="resTitleDetails"><span sa-data-type="custom_variable">BEC  &#60;150</span></li>    </div>    <div class="results-section-desc-title">        <p class="theTitle">Compared to baseline,* TEZSPIRE was shown to have a:</p>    </div>    <div class="thePercent">        <p class="theOutput"><span class="img01">&nbsp;</span><span class="theeResult"><strong>66%</strong></span> reduction in exacerbations*<sup>&#8224;</sup></p>        <p class="theOutput"><span class="img02">&nbsp;</span><span class="theeResult"><strong>68%</strong></span> reduction in exacerbations requiring hospitalizations, urgent care, or ED visits*<sup>&#8225;</sup></p>        <p class="theOutput"><span class="img03">&nbsp;</span><span class="theeResult"><strong>50</strong>&nbsp;</span><strong>mL</strong> improvement in FEV<sub>1</sub><sup>&#167;</sup></p>    </div>    <p class="may-vary-result">Individual results may vary.</p>    <div class="mainBtn">        <p class="theResBtnP"><a href="https://www.tezspirehcp.com/content/dam/open-digital/tezspirehcpday1/en/pdf/TEZSPIRE_Together_Program_Enrollment_Form.pdf" target="_blank" class="theResBtn">DOWNLOAD ENROLLMENT FORM</a></p>        <p class="theResBtnP"><a href="https://s.pointerpro.com/stvqpnnw" target="_self" class="calculateBtn">START OVER</a></p>    </div>    <div class="footerText">        <p class="theAnsFootNote">*Baseline defined as the mean number of exacerbations or exacerbations related to hospitalization or ER visits per patient in the 12 months prior to study enrollment. EOT defined as crude exacerbation rate (total number of exacerbations or exacerbations            related to hospitalization or ER visits that occurred over the total time at risk).</p>        <p class="theAnsFootNote"><sup>&#8224;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline <span class="theeResult">2.58</span>&nbsp;and EOT <span class="theeResult">0.87</span>&nbsp;(n=92); placebo + SOC baseline <span class="theeResult">2.58</span>&nbsp;and            EOT <span class="theeResult">1.44</span>&nbsp;(n=94; <span class="theeResult">44%</span>&nbsp;reduction from baseline).*</p>        <p class="theAnsFootNote"><sup>&#8225;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline <span class="theeResult">0.37</span>&nbsp;and EOT <span class="theeResult">0.12</span>&nbsp;(n=92); placebo + SOC baseline <span class="theeResult">0.63</span>&nbsp;and            EOT <span class="theeResult">0.24</span>&nbsp;(n=94; <span class="theeResult">62%</span>&nbsp;reduction from baseline).*</p>        <p class="theAnsFootNote"><sup>&#167;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline TEZSPIRE + SOC FEV<sub>1</sub> <span class="theeResult">0.05 L</span>&nbsp;(n=92) vs placebo + SOC FEV<sub>1</sub> <span class="theeResult">0.11 L</span>&nbsp;(n=94);            LS mean difference <span class="theeResult">-0.06</span> L&nbsp;(95% CI: -0.17-0.06). </p>        <p class="theAnsFootNote">AAER=annualized asthma exacerbation rate; BEC=blood eosinophil count; ED=emergency department; EOT=end of treatment; FEV<sub>1</sub>=forced expiratory volume in 1 second; LS=least-squares; SOC=standard of care.</p>    </div></div><div class="bottomPart">    <div id="content-end"></div></div>';

        var outcome2 = '<div class="topContainer"><div class="results-section"><p class="response-title-section">In patients with :</p><li class="resTitleDetails"><span sa-data-type="custom_variable">Positive allergic status</span></li><li class="resTitleDetails"><span sa-data-type="custom_variable">BEC 150-299</span></li></div><div class="results-section-desc-title"><p class="theTitle">Compared to baseline,* TEZSPIRE was shown to have a:</p></div><div class="thePercent"><p class="theOutput"><span class="img01">&nbsp;</span><span class="theeResult"><strong>77%</strong></span>reduction in exacerbations*<sup>&#8224;</sup></p><p class="theOutput"><span class="img02">&nbsp;</span><span class="theeResult"><strong>96%</strong></span>reduction in exacerbations requiring hospitalizations, urgent care, or ED visits*<sup>&#8225;</sup></p><p class="theOutput"><span class="img03">&nbsp;</span><span class="theeResult"><strong>120</strong>&nbsp;</span><strong>mL</strong>improvement in FEV<sub>1</sub><sup>&#167;</sup></p></div><p class="may-vary-result">Individual results may vary.</p><div class="mainBtn"><p class="theResBtnP"><a href="https://www.tezspirehcp.com/content/dam/open-digital/tezspirehcpday1/en/pdf/TEZSPIRE_Together_Program_Enrollment_Form.pdf" target="_blank" class="theResBtn">DOWNLOAD ENROLLMENT FORM</a></p><p class="theResBtnP"><a href="https://s.pointerpro.com/stvqpnnw" target="_self" class="calculateBtn">START OVER</a></p></div><div class="footerText"><p class="theAnsFootNote">*Baseline defined as the mean number of exacerbations or exacerbations related to hospitalization or ER visits per patient in the 12 months prior to study enrollment. EOT defined as crude exacerbation rate (total number of exacerbations or exacerbations related to hospitalization or ER visits that occurred over the total time at risk).</p><p class="theAnsFootNote"><sup>&#8224;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">2.60</span>&nbsp;and EOT<span class="theeResult">0.60</span>&nbsp;(n=137); placebo + SOC baseline<span class="theeResult">2.42</span>&nbsp;and EOT<span class="theeResult">1.28</span>&nbsp;(n=132;<span class="theeResult">47%</span>&nbsp;reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#8225;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">0.47</span>&nbsp;and EOT<span class="theeResult">0.02</span>&nbsp;(n=137); placebo + SOC baseline<span class="theeResult">0.33</span>&nbsp;and EOT<span class="theeResult">0.24</span>&nbsp;(n=132;<span class="theeResult">67%</span>&nbsp;reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#167;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline TEZSPIRE + SOC FEV<sub>1</sub><span class="theeResult">0.12</span>L&nbsp;(n=134) vs placebo + SOC FEV<sub>1</sub><span class="theeResult">0.10</span>L&nbsp;(n=132); LS mean difference<span class="theeResult">0.02</span>L&nbsp;(95% CI: -0.07-0.12).</p><p class="theAnsFootNote">AAER=annualized asthma exacerbation rate; BEC=blood eosinophil count; ED=emergency department; EOT=end of treatment; FEV<sub>1</sub>=forced expiratory volume in 1 second; LS=least-squares; SOC=standard of care.</p></div></div><div class="bottomPart"><div id="content-end"></div></div>';

        var outcome3 = '<div class="topContainer"><div class="results-section"><p class="response-title-section">In patients with :</p><li class="resTitleDetails"><span sa-data-type="custom_variable">Positive allergic status</span></li><li class="resTitleDetails"><span sa-data-type="custom_variable">BEC 300-449</span></li></div><div class="results-section-desc-title"><p class="theTitle">Compared to baseline,* TEZSPIRE was shown to have a:</p></div><div class="thePercent"><p class="theOutput"><span class="img01">&nbsp;</span><span class="theeResult"><strong>74%</strong></span>reduction in exacerbations*<sup>&#8224;</sup></p><p class="theOutput"><span class="img02">&nbsp;</span><span class="theeResult"><strong>92%</strong></span>reduction in exacerbations requiring hospitalizations, urgent care, or ED visits*<sup>&#8225;</sup></p><p class="theOutput"><span class="img03">&nbsp;</span><span class="theeResult"><strong>300</strong>&nbsp;</span><strong>mL</strong>improvement in FEV<sub>1</sub><sup>&#167;</sup></p></div><p class="may-vary-result">Individual results may vary.</p><div class="mainBtn"><p class="theResBtnP"><a href="https://www.tezspirehcp.com/content/dam/open-digital/tezspirehcpday1/en/pdf/TEZSPIRE_Together_Program_Enrollment_Form.pdf" target="_blank" class="theResBtn">DOWNLOAD ENROLLMENT FORM</a></p><p class="theResBtnP"><a href="https://s.pointerpro.com/stvqpnnw" target="_self" class="calculateBtn">START OVER</a></p></div><div class="footerText"><p class="theAnsFootNote">*Baseline defined as the mean number of exacerbations or exacerbations related to hospitalization or ER visits per patient in the 12 months prior to study enrollment. EOT defined as crude exacerbation rate (total number of exacerbations or exacerbations related to hospitalization or ER visits that occurred over the total time at risk).</p><p class="theAnsFootNote"><sup>&#8224;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">2.96</span>&nbsp;and EOT<span class="theeResult">0.76</span>&nbsp;(n=83); placebo + SOC baseline<span class="theeResult">2.71</span>&nbsp;and EOT<span class="theeResult">1.42</span>&nbsp;(n=73;<span class="theeResult">48%</span>&nbsp;reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#8225;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">0.51</span>&nbsp;and EOT<span class="theeResult">0.04</span>&nbsp;(n=83); placebo + SOC baseline<span class="theeResult">0.34</span>&nbsp;and EOT<span class="theeResult">0.14</span>&nbsp;(n=73;<span class="theeResult">59%</span>&nbsp;reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#167;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline TEZSPIRE + SOC FEV<sub>1</sub><span class="theeResult">0.30</span>L&nbsp;(n=82) vs placebo + SOC FEV<sub>1</sub><span class="theeResult">0.12</span>L&nbsp;(n=72); LS mean difference<span class="theeResult">0.18</span>L&nbsp;(95% CI: 0.05-0.31).</p><p class="theAnsFootNote">AAER=annualized asthma exacerbation rate; BEC=blood eosinophil count; ED=emergency department; EOT=end of treatment; FEV<sub>1</sub>=forced expiratory volume in 1 second; LS=least-squares; SOC=standard of care.</p></div></div><div class="bottomPart"><div id="content-end"></div></div>';

        var outcome4 = '<div class="topContainer"><div class="results-section"><p class="response-title-section">In patients with :</p><li class="resTitleDetails"><span sa-data-type="custom_variable">Positive allergic status</span></li><li class="resTitleDetails"><span sa-data-type="custom_variable">BEC â‰¥450</span></li></div><div class="results-section-desc-title"><p class="theTitle">Compared to baseline,* TEZSPIRE was shown to have a:</p></div><div class="thePercent"><p class="theOutput"><span class="img01">&nbsp;</span><span class="theeResult"><strong>82%</strong></span>reduction in exacerbations*<sup>&#8224;</sup></p><p class="theOutput"><span class="img02">&nbsp;</span><span class="theeResult"><strong>92%</strong></span>reduction in exacerbations requiring hospitalizations, urgent care, or ED visits*<sup>&#8225;</sup></p><p class="theOutput"><span class="img03"><strong>&nbsp;</strong></span><span class="theeResult"><strong>440</strong>&nbsp;</span><strong>mL</strong>improvement in FEV<sub>1</sub><sup>&#167;</sup></p></div><p class="may-vary-result">Individual results may vary.</p><div class="mainBtn"><p class="theResBtnP"><a href="https://www.tezspirehcp.com/content/dam/open-digital/tezspirehcpday1/en/pdf/TEZSPIRE_Together_Program_Enrollment_Form.pdf" target="_blank" class="theResBtn">DOWNLOAD ENROLLMENT FORM</a></p><p class="theResBtnP"><a href="https://s.pointerpro.com/stvqpnnw" target="_self" class="calculateBtn">START OVER</a></p></div><div class="footerText"><p class="theAnsFootNote">*Baseline defined as the mean number of exacerbations or exacerbations related to hospitalization or ER visits per patient in the 12 months prior to study enrollment. EOT defined as crude exacerbation rate (total number of exacerbations or exacerbations related to hospitalization or ER visits that occurred over the total time at risk).</p><p class="theAnsFootNote"><sup>&#8224;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">2.96</span>&nbsp;and EOT<span class="theeResult">0.52</span>&nbsp;(n=98); placebo + SOC baseline<span class="theeResult">3.10</span>&nbsp;and EOT<span class="theeResult">2.20</span>&nbsp;(n=106;<span class="theeResult">29%</span>&nbsp;reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#8225;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">0.38</span>&nbsp;and EOT<span class="theeResult">0.03</span>&nbsp;(n=98); placebo + SOC baseline<span class="theeResult">0.56</span>&nbsp;and EOT<span class="theeResult">0.29</span>&nbsp;(n=106;<span class="theeResult">48%</span>&nbsp;reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#167;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline TEZSPIRE + SOC FEV<sub>1</sub><span class="theeResult">0.44</span>L&nbsp;(n=98) vs placebo + SOC FEV<sub>1</sub><span class="theeResult">0.20</span>L&nbsp;(n=106); LS mean difference<span class="theeResult">0.24</span>L&nbsp;(95% CI: 0.13-0.35).</p><p class="theAnsFootNote">AAER=annualized asthma exacerbation rate; BEC=blood eosinophil count; ED=emergency department; EOT=end of treatment; FEV<sub>1</sub>=forced expiratory volume in 1 second; LS=least-squares; SOC=standard of care.</p></div></div><div class="bottomPart"><div id="content-end"></div></div>';

        var outcome5 = '<div class="topContainer"><div class="results-section"><p class="response-title-section">In patients with :</p><li class="resTitleDetails"><span sa-data-type="custom_variable">Positive allergic status</span></li><li class="resTitleDetails"><span sa-data-type="custom_variable">Unknown BEC level</span></li></div><div class="results-section-desc-title"><p class="theTitle">Compared to baseline,* TEZSPIRE was shown to have a:</p></div><div class="thePercent"><p class="theOutput"><span class="img01">&nbsp;</span><span class="theeResult"><strong>76%</strong></span>reduction in exacerbations*<sup>&#8224;</sup></p><p class="theOutput"><span class="img02">&nbsp;</span><span class="theeResult"><strong>88%</strong></span>reduction in exacerbations requiring hospitalizations, urgent care, or ED visits*<sup>&#8225;</sup></p><p class="theOutput"><span class="img03">&nbsp;</span><span class="theeResult"><strong>220</strong>&nbsp;</span><strong>mL</strong>improvement in FEV<sub>1</sub><sup>&#167;</sup></p></div><p class="may-vary-result">Individual results may vary.</p><div class="mainBtn"><p class="theResBtnP"><a href="https://www.tezspirehcp.com/content/dam/open-digital/tezspirehcpday1/en/pdf/TEZSPIRE_Together_Program_Enrollment_Form.pdf" target="_blank" class="theResBtn">DOWNLOAD ENROLLMENT FORM</a></p><p class="theResBtnP"><a href="https://s.pointerpro.com/stvqpnnw" target="_self" class="calculateBtn">START OVER</a></p></div><div class="footerText"><p class="theAnsFootNote">*Baseline defined as the mean number of exacerbations or exacerbations related to hospitalization or ER visits per patient in the 12 months prior to study enrollment. EOT defined as crude exacerbation rate (total number of exacerbations or exacerbations related to hospitalization or ER visits that occurred over the total time at risk).</p><p class="theAnsFootNote"><sup>&#8224;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">2.75</span>&nbsp;and EOT<span class="theeResult">0.67</span>&nbsp;(n=410); placebo + SOC baseline<span class="theeResult">2.68</span>&nbsp;and EOT<span class="theeResult">1.58</span>&nbsp;(n=405;<span class="theeResult">41%</span>&nbsp;reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#8224;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">0.43</span>&nbsp;and EOT<span class="theeResult">0.05</span>&nbsp;(n=410); placebo + SOC baseline<span class="theeResult">0.46</span>&nbsp;and EOT<span class="theeResult">0.19</span>&nbsp;(n=405;<span class="theeResult">59%</span>&nbsp;reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#167;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline TEZSPIRE + SOC FEV<sub>1</sub><span class="theeResult">0.22</span>L&nbsp;(n=383) vs placebo + SOC FEV<sub>1</sub><span class="theeResult">0.13</span>L&nbsp;(n=379); LS mean difference<span class="theeResult">0.09</span>L&nbsp;(95% CI: 0.03-0.14).</p><p class="theAnsFootNote">AAER=annualized asthma exacerbation rate; BEC=blood eosinophil count; ED=emergency department; EOT=end of treatment; FEV<sub>1</sub>=forced expiratory volume in 1 second; LS=least-squares; SOC=standard of care.</p></div></div><div class="bottomPart"><div id="content-end"></div></div>';

        var outcome6 = '<div class="topContainer"><div class="results-section"><p class="response-title-section">In patients with :</p><li class="resTitleDetails"><span sa-data-type="custom_variable">Negative allergic status</span></li><li class="resTitleDetails"><span sa-data-type="custom_variable">BEC &#60;150</span></li></div><div class="results-section-desc-title"><p class="theTitle">Compared to baseline,* TEZSPIRE was shown to have a:</p></div><div class="thePercent"><p class="theOutput"><span class="img01">&nbsp;</span><span class="theeResult"><strong>69%</strong></span>reduction in exacerbations*<sup>&#8224;</sup></p><p class="theOutput"><span class="img02">&nbsp;</span><span class="theeResult"><strong>74%</strong></span>reduction in exacerbations requiring hospitalizations, urgent care, or ED visits*<sup>&#8225;</sup></p><p class="theOutput"><span class="img03">&nbsp;</span><span class="theeResult"><strong>90</strong>&nbsp;</span><strong>mL</strong>improvement in FEV<sub>1</sub><sup>&#167;</sup></p></div><p class="may-vary-result">Individual results may vary.</p><div class="mainBtn"><p class="theResBtnP"><a href="https://www.tezspirehcp.com/content/dam/open-digital/tezspirehcpday1/en/pdf/TEZSPIRE_Together_Program_Enrollment_Form.pdf" target="_blank" class="theResBtn">DOWNLOAD ENROLLMENT FORM</a></p><p class="theResBtnP"><a href="https://s.pointerpro.com/stvqpnnw" target="_self" class="calculateBtn">START OVER</a></p></div><div class="footerText"><p class="theAnsFootNote">*Baseline defined as the mean number of exacerbations or exacerbations related to hospitalization or ER visits per patient in the 12 months prior to study enrollment. EOT defined as crude exacerbation rate (total number of exacerbations or exacerbations related to hospitalization or ER visits that occurred over the total time at risk).</p><p class="theAnsFootNote"><sup>&#8224;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">2.55</span>&nbsp;and EOT<span class="theeResult">0.79</span>&nbsp;(n=71); placebo + SOC baseline<span class="theeResult">2.51</span>&nbsp;and EOT<span class="theeResult">1.46</span>&nbsp;(n=69;<span class="theeResult">42%&nbsp;</span>reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#8225;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">0.39</span>&nbsp;and EOT<span class="theeResult">0.10</span>&nbsp;(n=71); placebo + SOC baseline<span class="theeResult">0.51</span>&nbsp;and EOT<span class="theeResult">0.27</span>&nbsp;(n=69;<span class="theeResult">47%</span>&nbsp;reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#167;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline TEZSPIRE + SOC FEV<sub>1</sub><span class="theeResult">0.09</span>L&nbsp;(n=71) vs placebo + SOC FEV<sub>1</sub><span class="theeResult">0.02</span>L&nbsp;(n=69); LS mean difference<span class="theeResult">0.08</span>L&nbsp;(95% CI: -0.06-0.21).</p><p class="theAnsFootNote">AAER=annualized asthma exacerbation rate; BEC=blood eosinophil count; ED=emergency department; EOT=end of treatment; FEV<sub>1</sub>=forced expiratory volume in 1 second; LS=least-squares; SOC=standard of care.</p></div></div><div class="bottomPart"><div id="content-end"></div></div>';

        var outcome7 = '<div class="topContainer"><div class="results-section"><p class="response-title-section">In patients with :</p><li class="resTitleDetails"><span sa-data-type="custom_variable">Negative allergic status</span></li><li class="resTitleDetails"><span sa-data-type="custom_variable">BEC 150-299</span></li></div><div class="results-section-desc-title"><p class="theTitle">Compared to baseline,* TEZSPIRE was shown to have a:</p></div><div class="thePercent"><p class="theOutput"><span class="img01">&nbsp;</span><span class="theeResult"><strong>59%</strong></span>reduction in exacerbations*<sup>&#8224;</sup></p><p class="theOutput"><span class="img02">&nbsp;</span><span class="theeResult"><strong>88%</strong></span>reduction in exacerbations requiring hospitalizations, urgent care, or ED visits*<sup>&#8225;</sup></p><p class="theOutput"><span class="img03">&nbsp;</span><span class="theeResult"><strong>200</strong>&nbsp;</span><strong>mL</strong>improvement in FEV<sub>1</sub><sup>&#167;</sup></p></div><p class="may-vary-result">Individual results may vary.</p><div class="mainBtn"><p class="theResBtnP"><a href="https://www.tezspirehcp.com/content/dam/open-digital/tezspirehcpday1/en/pdf/TEZSPIRE_Together_Program_Enrollment_Form.pdf" target="_blank" class="theResBtn">DOWNLOAD ENROLLMENT FORM</a></p><p class="theResBtnP"><a href="https://s.pointerpro.com/stvqpnnw" target="_self" class="calculateBtn">START OVER</a></p></div><div class="footerText"><p class="theAnsFootNote">*Baseline defined as the mean number of exacerbations or exacerbations related to hospitalization or ER visits per patient in the 12 months prior to study enrollment. EOT defined as crude exacerbation rate (total number of exacerbations or exacerbations related to hospitalization or ER visits that occurred over the total time at risk).</p><p class="theAnsFootNote"><sup>&#8224;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">2.64</span>&nbsp;and EOT<span class="theeResult">1.08</span>&nbsp;(n=74); placebo + SOC baseline<span class="theeResult">2.78</span>&nbsp;and EOT<span class="theeResult">1.46</span>&nbsp;(n=74;<span class="theeResult">47%</span>&nbsp;reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#8225;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">0.51</span>&nbsp;and EOT<span class="theeResult">0.06</span>&nbsp;(n=74); placebo + SOC baseline<span class="theeResult">0.28</span>&nbsp;and EOT<span class="theeResult">0.15</span>&nbsp;(n=74;<span class="theeResult">46%</span>&nbsp;reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#167;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline TEZSPIRE + SOC FEV<sub>1</sub><span class="theeResult">0.20</span>L&nbsp;(n=73) vs placebo + SOC FEV<sub>1</sub><span class="theeResult">-0.04</span>L&nbsp;(n=73); LS mean difference<span class="theeResult">0.23</span>L&nbsp;(95% CI: 0.10-0.36).</p><p class="theAnsFootNote">AAER=annualized asthma exacerbation rate; BEC=blood eosinophil count; ED=emergency department; EOT=end of treatment; FEV<sub>1</sub>=forced expiratory volume in 1 second; LS=least-squares; SOC=standard of care.</p></div></div><div class="bottomPart"><div id="content-end"></div></div>';

        var outcome8 = '<div class="topContainer"><div class="results-section"><p class="response-title-section">In patients with :</p><li class="resTitleDetails"><span sa-data-type="custom_variable">Negative allergic status</span></li><li class="resTitleDetails"><span sa-data-type="custom_variable">BEC 300-449</span></li></div><div class="results-section-desc-title"><p class="theTitle">Compared to baseline,* TEZSPIRE was shown to have a:</p></div><div class="thePercent"><p class="theOutput"><span class="img01">&nbsp;</span><span class="theeResult"><strong>71%</strong></span>reduction in exacerbations*<sup>&#8224;</sup></p><p class="theOutput"><span class="img02">&nbsp;</span><span class="theeResult"><strong>100%</strong></span>reduction in exacerbations requiring hospitalizations, urgent care, or ED visits*<sup>&#8225;</sup></p><p class="theOutput"><span class="img03">&nbsp;</span><span class="theeResult"><strong>280</strong>&nbsp;</span><strong>mL</strong>improvement in FEV<sub>1</sub><sup>&#167;</sup></p></div><p class="may-vary-result">Individual results may vary.</p><div class="mainBtn"><p class="theResBtnP"><a href="https://www.tezspirehcp.com/content/dam/open-digital/tezspirehcpday1/en/pdf/TEZSPIRE_Together_Program_Enrollment_Form.pdf" target="_blank" class="theResBtn">DOWNLOAD ENROLLMENT FORM</a></p><p class="theResBtnP"><a href="https://s.pointerpro.com/stvqpnnw" target="_self" class="calculateBtn">START OVER</a></p></div><div class="footerText"><p class="theAnsFootNote">*Baseline defined as the mean number of exacerbations or exacerbations related to hospitalization or ER visits per patient in the 12 months prior to study enrollment. EOT defined as crude exacerbation rate (total number of exacerbations or exacerbations related to hospitalization or ER visits that occurred over the total time at risk).</p><p class="theAnsFootNote"><sup>&#8224;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">2.51</span>&nbsp;and EOT<span class="theeResult">0.72</span>&nbsp;(n=39); placebo + SOC baseline<span class="theeResult">2.80</span>&nbsp;and EOT<span class="theeResult">1.85</span>&nbsp;(n=40;<span class="theeResult">34%</span>&nbsp;reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#8225;</sup>Post hoc analysis&nbsp;of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">0.21</span>&nbsp;and EOT<span class="theeResult">0.00</span>&nbsp;(n=39); placebo + SOC baseline<span class="theeResult">0.90</span>&nbsp;and EOT<span class="theeResult">0.36</span>&nbsp;(n=40;<span class="theeResult">60%</span>&nbsp;reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#167;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline TEZSPIRE + SOC FEV<sub>1</sub><span class="theeResult">0.28</span>L&nbsp;(n=39) vs placebo + SOC FEV<sub>1</sub><span class="theeResult">0.02</span>L&nbsp;(n=40); LS mean difference<span class="theeResult">0.27</span>L&nbsp;(95% CI: 0.09-0.44).</p><p class="theAnsFootNote">AAER=annualized asthma exacerbation rate; BEC=blood eosinophil count; ED=emergency department; EOT=end of treatment; FEV<sub>1</sub>=forced expiratory volume in 1 second; LS=least-squares; SOC=standard of care.</p></div></div><div class="bottomPart"><div id="content-end"></div></div>';

        var outcome9 = '<div class="topContainer"><div class="results-section"><p class="response-title-section">In patients with :</p><li class="resTitleDetails"><span sa-data-type="custom_variable">Negative allergic status</span></li><li class="resTitleDetails"><span sa-data-type="custom_variable">BEC â‰¥450</span></li></div><div class="results-section-desc-title"><p class="theTitle">Compared to baseline,* TEZSPIRE was shown to have a:</p></div><div class="thePercent"><p class="theOutput"><span class="img01">&nbsp;</span><span class="theeResult"><strong>82%</strong></span>reduction in exacerbations*<sup>&#8224;</sup></p><p class="theOutput"><span class="img02">&nbsp;</span><span class="theeResult"><strong>92%</strong></span>reduction in exacerbations requiring hospitalizations, urgent care, or ED visits*<sup>&#8225;</sup></p><p class="theOutput"><span class="img03">&nbsp;</span><span class="theeResult"><strong>420&nbsp;</strong></span><strong>mL</strong>improvement in FEV<sub>1</sub><sup>&#167;</sup></p></div><p class="may-vary-result">Individual results may vary.</p><div class="mainBtn"><p class="theResBtnP"><a href="https://www.tezspirehcp.com/content/dam/open-digital/tezspirehcpday1/en/pdf/TEZSPIRE_Together_Program_Enrollment_Form.pdf" target="_blank" class="theResBtn">DOWNLOAD ENROLLMENT FORM</a></p><p class="theResBtnP"><a href="https://s.pointerpro.com/stvqpnnw" target="_self" class="calculateBtn">START OVER</a></p></div><div class="footerText"><p class="theAnsFootNote">*Baseline defined as the mean number of exacerbations or exacerbations related to hospitalization or ER visits per patient in the 12 months prior to study enrollment. EOT defined as crude exacerbation rate (total number of exacerbations or exacerbations related to hospitalization or ER visits that occurred over the total time at risk).</p><p class="theAnsFootNote"><sup>&#8224;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">3.04</span>&nbsp;and EOT<span class="theeResult">0.55</span>&nbsp;(n=57); placebo + SOC baseline<span class="theeResult">2.58</span>&nbsp;and EOT<span class="theeResult">2.02</span>&nbsp;(n=60;<span class="theeResult">22%</span>&nbsp;reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#8225;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">0.60</span>&nbsp;and EOT<span class="theeResult">0.05</span>&nbsp;(n=57); placebo + SOC baseline<span class="theeResult">0.62</span>&nbsp;and EOT<span class="theeResult">0.24</span>&nbsp;(n=60;<span class="theeResult">61%</span>&nbsp;reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#167;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline TEZSPIRE + SOC FEV<sub>1</sub><span class="theeResult">0.42</span>L&nbsp;(n=57) vs placebo + SOC FEV<sub>1</sub><span class="theeResult">0.13</span>L&nbsp;(n=60); LS mean difference<span class="theeResult">0.29</span>L&nbsp;(95% CI: 0.14-0.43).</p><p class="theAnsFootNote">AAER=annualized asthma exacerbation rate; BEC=blood eosinophil count; ED=emergency department; EOT=end of treatment; FEV<sub>1</sub>=forced expiratory volume in 1 second; LS=least-squares; SOC=standard of care.</p></div></div><div class="bottomPart"><div id="content-end"></div></div>';

        var outcome10 = '<div class="topContainer"><div class="results-section"><p class="response-title-section">In patients with :</p><li class="resTitleDetails"><span sa-data-type="custom_variable">Negative allergic status</span></li><li class="resTitleDetails"><span sa-data-type="custom_variable">Unknown BEC level</span></li></div><div class="results-section-desc-title"><p class="theTitle">Compared to baseline,* TEZSPIRE was shown to have a:</p></div><div class="thePercent"><p class="theOutput"><span class="img01">&nbsp;</span><span class="theeResult"><strong>70%</strong></span>reduction in exacerbations*<sup>&#8224;</sup></p><p class="theOutput"><span class="img02">&nbsp;</span><span class="theeResult"><strong>87%</strong></span>reduction in exacerbations requiring hospitalizations, urgent care, or ED visits*<sup>&#8225;</sup></p><p class="theOutput"><span class="img03">&nbsp;</span><span class="theeResult"><strong>230</strong>&nbsp;</span><strong>mL</strong>improvement in FEV<sub>1</sub><sup>&#167;</sup></p></div><p class="may-vary-result">Individual results may vary.</p><div class="mainBtn"><p class="theResBtnP"><a href="https://www.tezspirehcp.com/content/dam/open-digital/tezspirehcpday1/en/pdf/TEZSPIRE_Together_Program_Enrollment_Form.pdf" target="_blank" class="theResBtn">DOWNLOAD ENROLLMENT FORM</a></p><p class="theResBtnP"><a href="https://s.pointerpro.com/stvqpnnw" target="_self" class="calculateBtn">START OVER</a></p></div><div class="footerText"><p class="theAnsFootNote">*Baseline defined as the mean number of exacerbations or exacerbations related to hospitalization or ER visits per patient in the 12 months prior to study enrollment. EOT defined as crude exacerbation rate (total number of exacerbations or exacerbations related to hospitalization or ER visits that occurred over the total time at risk).</p><p class="theAnsFootNote"><sup>&#8224;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">2.68</span>&nbsp;and EOT<span class="theeResult">0.81</span>&nbsp;(n=241); placebo + SOC baseline<span class="theeResult">2.66</span>&nbsp;and EOT<span class="theeResult">1.66</span>&nbsp;(n=243;<span class="theeResult">38%</span>&nbsp;reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#8225;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">0.45</span>&nbsp;and EOT<span class="theeResult">0.06</span>&nbsp;(n=241); placebo + SOC baseline<span class="theeResult">0.53</span>&nbsp;and EOT<span class="theeResult">0.24</span>&nbsp;(n=243;<span class="theeResult">55%</span>&nbsp;reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#167;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline TEZSPIRE + SOC FEV<sub>1</sub><span class="theeResult">0.23</span>L&nbsp;(n=228) vs placebo + SOC FEV<sub>1</sub><span class="theeResult">0.03</span>L&nbsp;(n=221); LS mean difference<span class="theeResult">0.20</span>L&nbsp;(95% CI: 0.13-0.28).</p><p class="theAnsFootNote">AAER=annualized asthma exacerbation rate; BEC=blood eosinophil count; ED=emergency department; EOT=end of treatment; FEV<sub>1</sub>=forced expiratory volume in 1 second; LS=least-squares; SOC=standard of care.</p></div></div><div class="bottomPart"><div id="content-end"></div></div>';

        var outcome11 = '<div class="topContainer"><div class="results-section"><p class="response-title-section">In patients with :</p><li class="resTitleDetails"><span sa-data-type="custom_variable">Unknown allergic status</span></li><li class="resTitleDetails"><span sa-data-type="custom_variable">BEC &#60;150</span></li></div><div class="results-section-desc-title"><p class="theTitle">Compared to baseline,* TEZSPIRE was shown to have a:</p></div><div class="thePercent"><p class="theOutput"><span class="img01">&nbsp;</span><span class="theeResult"><strong>68%</strong></span>reduction in exacerbations*<sup>&#8224;</sup></p><p class="theOutput"><span class="img02">&nbsp;</span><span class="theeResult"><strong>73%</strong></span>reduction in exacerbations requiring hospitalizations, urgent care, or ED visits*<sup>&#8225;</sup></p><p class="theOutput"><span class="img03">&nbsp;</span><span class="theeResult"><strong>70</strong>&nbsp;</span><strong>mL</strong>improvement in FEV<sub>1</sub><sup>&#167;</sup></p></div><p class="may-vary-result">Individual results may vary.</p><div class="mainBtn"><p class="theResBtnP"><a href="https://www.tezspirehcp.com/content/dam/open-digital/tezspirehcpday1/en/pdf/TEZSPIRE_Together_Program_Enrollment_Form.pdf" target="_self" class="theResBtn">DOWNLOAD ENROLLMENT FORM</a></p><p class="theResBtnP"><a href="https://s.pointerpro.com/stvqpnnw" class="calculateBtn">START OVER</a></p></div><div class="footerText"><p class="theAnsFootNote">*Baseline defined as the mean number of exacerbations or exacerbations related to hospitalization or ER visits per patient in the 12 months prior to study enrollment. EOT defined as crude exacerbation rate (total number of exacerbations or exacerbations related to hospitalization or ER visits that occurred over the total time at risk).</p><p class="theAnsFootNote"><sup>&#8224;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">2.55</span>and EOT<span class="theeResult">0.82</span>(n=166); placebo + SOC baseline<span class="theeResult">2.56</span>and EOT<span class="theeResult">1.45</span>(n=171;<span class="theeResult">43%</span>reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#8225;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">0.40</span>and EOT<span class="theeResult">0.11</span>(n=166); placebo + SOC baseline<span class="theeResult">0.58</span>and EOT<span class="theeResult">0.29</span>(n=171;<span class="theeResult">50%</span>reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#167;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline TEZSPIRE + SOC FEV<sub>1</sub>0.07 L (n=155) vs placebo + SOC FEV<sub>1</sub>0.07 L (n=157); LS mean difference 0.00 L (95% CI: -0.09-0.08).</p><p class="theAnsFootNote">AAER=annualized asthma exacerbation rate; BEC=blood eosinophil count; ED=emergency department; EOT=end of treatment; FEV<sub>1</sub>=forced expiratory volume in 1 second; LS=least-squares; SOC=standard of care.</p></div></div><div class="bottomPart"><div id="content-end"></div></div>';

        var outcome12 = '<div class="topContainer"><div class="results-section"><p class="response-title-section">In patients with :</p><li class="resTitleDetails"><span sa-data-type="custom_variable">Unknown allergic status</span></li><li class="resTitleDetails"><span sa-data-type="custom_variable">BEC 150-299</span></li></div><div class="results-section-desc-title"><p class="theTitle">Compared to baseline,* TEZSPIRE was shown to have a:</p></div><div class="thePercent"><p class="theOutput"><span class="img01">&nbsp;</span><span class="theeResult"><strong>71%</strong></span>reduction in exacerbations*<sup>&#8224;</sup></p><p class="theOutput"><strong><span class="img02">&nbsp;</span><span class="theeResult">94%</span></strong>reduction in exacerbations requiring hospitalizations, urgent care, or ED visits*<sup>&#8225;</sup></p><p class="theOutput"><span class="img03">&nbsp;</span><span class="theeResult"><strong>150</strong>&nbsp;</span><strong>mL</strong>improvement in FEV<sub>1</sub><sup>&#167;</sup></p></div><p class="may-vary-result">Individual results may vary.</p><div class="mainBtn"><p class="theResBtnP"><a href="https://www.tezspirehcp.com/content/dam/open-digital/tezspirehcpday1/en/pdf/TEZSPIRE_Together_Program_Enrollment_Form.pdf" target="_blank" class="theResBtn">DOWNLOAD ENROLLMENT FORM</a></p><p class="theResBtnP"><a href="https://s.pointerpro.com/stvqpnnw" target="_self" class="calculateBtn">START OVER</a></p></div><div class="footerText"><p class="theAnsFootNote">*Baseline defined as the mean number of exacerbations or exacerbations related to hospitalization or ER visits per patient in the 12 months prior to study enrollment. EOT defined as crude exacerbation rate (total number of exacerbations or exacerbations related to hospitalization or ER visits that occurred over the total time at risk).</p><p class="theAnsFootNote"><sup>&#8224;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">2.61</span>&nbsp;and EOT<span class="theeResult">0.76</span>&nbsp;(n=213); placebo + SOC baseline<span class="theeResult">2.58</span>&nbsp;and EOT<span class="theeResult">1.36</span>&nbsp;(n=211;<span class="theeResult">47%</span>&nbsp;reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#8225;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">0.48</span>&nbsp;and EOT<span class="theeResult">0.03</span>&nbsp;(n=231); placebo + SOC baseline<span class="theeResult">0.31</span>&nbsp;and EOT<span class="theeResult">0.13</span>&nbsp;(n=211;<span class="theeResult">58%</span>&nbsp;reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#167;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline TEZSPIRE + SOC FEV<sub>1</sub><span class="theeResult">0.15</span>L&nbsp;(n=200) vs placebo + SOC FEV<sub>1</sub><span class="theeResult">0.05</span>L&nbsp;(n=197); LS mean difference<span class="theeResult">0.10</span>L&nbsp;(95% CI: 0.02-0.18).</p><p class="theAnsFootNote">AAER=annualized asthma exacerbation rate; BEC=blood eosinophil count; ED=emergency department; EOT=end of treatment; FEV<sub>1</sub>=forced expiratory volume in 1 second; LS=least-squares; SOC=standard of care.</p></div></div><div class="bottomPart"><div id="content-end"></div></div>';

        var outcome13 = '<div class="topContainer"><div class="results-section"><p class="response-title-section">In patients with :</p><li class="resTitleDetails"><span sa-data-type="custom_variable">Unknown allergic status</span></li><li class="resTitleDetails"><span sa-data-type="custom_variable">BEC 300-449</span></li></div><div class="results-section-desc-title"><p class="theTitle">Compared to baseline,* TEZSPIRE was shown to have a:</p></div><div class="thePercent"><p class="theOutput"><span class="img01">&nbsp;</span><strong><span class="theeResult">73%</span></strong>reduction in exacerbations*<sup>&#8224;</sup></p><p class="theOutput"><span class="img02">&nbsp;</span><span class="theeResult"><strong>95%</strong></span>reduction in exacerbations requiring hospitalizations, urgent care, or ED visits*<sup>&#8225;</sup></p><p class="theOutput"><span class="img03">&nbsp;</span><span class="theeResult"><strong>290</strong>&nbsp;</span><strong>mL</strong>improvement in FEV<sub>1</sub><sup>&#167;</sup></p></div><p class="may-vary-result">Individual results may vary.</p><div class="mainBtn"><p class="theResBtnP"><a href="https://www.tezspirehcp.com/content/dam/open-digital/tezspirehcpday1/en/pdf/TEZSPIRE_Together_Program_Enrollment_Form.pdf" target="_blank" class="theResBtn">DOWNLOAD ENROLLMENT FORM</a></p><p class="theResBtnP"><a href="https://s.pointerpro.com/stvqpnnw" target="_self" class="calculateBtn">START OVER</a></p></div><div class="footerText"><p class="theAnsFootNote">*Baseline defined as the mean number of exacerbations or exacerbations related to hospitalization or ER visits per patient in the 12 months prior to study enrollment. EOT defined as crude exacerbation rate (total number of exacerbations or exacerbations related to hospitalization or ER visits that occurred over the total time at risk).</p><p class="theAnsFootNote"><sup>&#8224;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">2.82</span>&nbsp;and EOT<span class="theeResult">0.75</span>&nbsp;(n=127); placebo + SOC baseline<span class="theeResult">2.73</span>&nbsp;and EOT<span class="theeResult">1.56</span>&nbsp;(n=116;<span class="theeResult">43%</span>&nbsp;reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#8225;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">0.41</span>&nbsp;and EOT<span class="theeResult">0.02</span>&nbsp;(n=127); placebo + SOC baseline<span class="theeResult">0.55</span>&nbsp;and EOT<span class="theeResult">0.21</span>&nbsp;(n=116;<span class="theeResult">62%</span>&nbsp;reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#167;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline TEZSPIRE + SOC FEV<sub>1</sub><span class="theeResult">0.29</span>L&nbsp;(n=119) vs placebo + SOC FEV<sub>1</sub><span class="theeResult">0.08</span>L&nbsp;(n=109); LS mean difference<span class="theeResult">0.21</span>L&nbsp;(95% CI: 0.11-0.31).</p><p class="theAnsFootNote">AAER=annualized asthma exacerbation rate; BEC=blood eosinophil count; ED=emergency department; EOT=end of treatment; FEV<sub>1</sub>=forced expiratory volume in 1 second; LS=least-squares; SOC=standard of care.</p></div></div><div class="bottomPart"><div id="content-end"></div></div>';

        var outcome14 = '<div class="topContainer"><div class="results-section"><p class="response-title-section">In patients with :</p><li class="resTitleDetails"><span sa-data-type="custom_variable">Unknown allergic status</span></li><li class="resTitleDetails"><span sa-data-type="custom_variable">BEC â‰¥450</span></li></div><div class="results-section-desc-title"><p class="theTitle">Compared to baseline,* TEZSPIRE was shown to have a:</p></div><div class="thePercent"><p class="theOutput"><span class="img01">&nbsp;</span><span class="theeResult"><strong>82%</strong></span>reduction in exacerbations*<sup>&#8224;</sup></p><p class="theOutput"><span class="img02">&nbsp;</span><strong><span class="theeResult">91%</span></strong>reduction in exacerbations requiring hospitalizations, urgent care, or ED visits*<sup>&#8225;</sup></p><p class="theOutput"><span class="img03">&nbsp;</span><span class="theeResult"><strong>440</strong><strong>&nbsp;</strong></span><strong>mL</strong>improvement in FEV<sub>1</sub><sup>&#167;</sup></p></div><p class="may-vary-result">Individual results may vary.</p><div class="mainBtn"><p class="theResBtnP"><a href="https://www.tezspirehcp.com/content/dam/open-digital/tezspirehcpday1/en/pdf/TEZSPIRE_Together_Program_Enrollment_Form.pdf" target="_blank" class="theResBtn">DOWNLOAD ENROLLMENT FORM</a></p><p class="theResBtnP"><a href="https://s.pointerpro.com/stvqpnnw" target="_self" class="calculateBtn">START OVER</a></p></div><div class="footerText"><p class="theAnsFootNote">*Baseline defined as the mean number of exacerbations or exacerbations related to hospitalization or ER visits per patient in the 12 months prior to study enrollment. EOT defined as crude exacerbation rate (total number of exacerbations or exacerbations related to hospitalization or ER visits that occurred over the total time at risk).</p><p class="theAnsFootNote"><sup>&#8224;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">2.98</span>&nbsp;and EOT<span class="theeResult">0.53</span>&nbsp;(n=159); placebo + SOC baseline<span class="theeResult">2.91</span>&nbsp;and EOT<span class="theeResult">2.11</span>&nbsp;(n=171;<span class="theeResult">27%</span>&nbsp;reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#8225;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">0.47</span>&nbsp;and EOT<span class="theeResult">0.04</span>&nbsp;(n=159); placebo + SOC baseline<span class="theeResult">0.56</span>&nbsp;and EOT<span class="theeResult">0.27</span>&nbsp;(n=171;<span class="theeResult">52%</span>&nbsp;reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#167;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline TEZSPIRE + SOC FEV<sub>1</sub><span class="theeResult">0.44</span>L&nbsp;(n=150) vs placebo + SOC FEV<sub>1</sub><span class="theeResult">0.17</span>L&nbsp;(n=156); LS mean difference<span class="theeResult">0.27</span>L&nbsp;(95% CI: 0.18-0.36).</p><p class="theAnsFootNote">AAER=annualized asthma exacerbation rate; BEC=blood eosinophil count; ED=emergency department; EOT=end of treatment; FEV<sub>1</sub>=forced expiratory volume in 1 second; LS=least-squares; SOC=standard of care.</p></div></div><div class="bottomPart"><div id="content-end"></div></div>';

        var outcome15 = '<div class="topContainer"><div class="results-section"><p class="response-title-section">In patients with :</p><li class="resTitleDetails"><span sa-data-type="custom_variable">Unknown allergic status</span></li><li class="resTitleDetails"><span sa-data-type="custom_variable">Unknown BEC level</span></li></div><div class="results-section-desc-title"><p class="theTitle">Compared to baseline,* TEZSPIRE was shown to have a:</p></div><div class="thePercent"><p class="theOutput"><span class="img01">&nbsp;</span><span class="theeResult"><strong>73%</strong></span>reduction in exacerbations*<sup>&#8224;</sup></p><p class="theOutput"><span class="img02">&nbsp;</span><span class="theeResult"><strong>87%</strong></span>reduction in exacerbations requiring hospitalizations, urgent care, or ED visits*<sup>&#8225;</sup></p><p class="theOutput"><span class="img03">&nbsp;</span><span class="theeResult"><strong>220</strong>&nbsp;</span><strong>mL</strong>improvement in FEV<sub>1</sub><sup>&#167;</sup></p></div><p class="may-vary-result">Individual results may vary.</p><div class="mainBtn"><p class="theResBtnP"><a href="https://www.tezspirehcp.com/content/dam/open-digital/tezspirehcpday1/en/pdf/TEZSPIRE_Together_Program_Enrollment_Form.pdf" target="_blank" class="theResBtn">DOWNLOAD ENROLLMENT FORM</a></p><p class="theResBtnP"><a href="https://s.pointerpro.com/stvqpnnw" target="_self" class="calculateBtn">START OVER</a></p></div><div class="footerText"><p class="theAnsFootNote">*Baseline defined as the mean number of exacerbations or exacerbations related to hospitalization or ER visits per patient in the 12 months prior to study enrollment. EOT defined as crude exacerbation rate (total number of exacerbations or exacerbations related to hospitalization or ER visits that occurred over the total time at risk).</p><p class="theAnsFootNote"><sup>&#8224;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">2.7</span>&nbsp;and EOT<span class="theeResult">0.72</span>&nbsp;(n=665); placebo + SOC baseline<span class="theeResult">2.7</span>&nbsp;and EOT<span class="theeResult">1.61</span>&nbsp;(n=669;<span class="theeResult">40%</span>&nbsp;reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#8225;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. TEZSPIRE + SOC baseline<span class="theeResult">0.44</span>&nbsp;and EOT<span class="theeResult">0.05</span>&nbsp;(n=665); placebo + SOC baseline<span class="theeResult">0.48</span>&nbsp;and EOT<span class="theeResult">0.22</span>&nbsp;(n=669;<span class="theeResult">54%</span>&nbsp;reduction from baseline).*</p><p class="theAnsFootNote"><sup>&#167;</sup>Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline TEZSPIRE + SOC FEV<sub>1</sub><span class="theeResult">0.22</span>L&nbsp;(n=624) vs placebo + SOC FEV<sub>1</sub><span class="theeResult">0.09</span>L&nbsp;(n=619); LS mean difference<span class="theeResult">0.13</span>L&nbsp;(95% CI: 0.09-0.18).</p><p class="theAnsFootNote">AAER=annualized asthma exacerbation rate; BEC=blood eosinophil count; ED=emergency department; EOT=end of treatment; FEV<sub>1</sub>=forced expiratory volume in 1 second; LS=least-squares; SOC=standard of care.</p></div></div><div class="bottomPart"><div id="content-end"></div></div>';

        if (allergicStatus === "allergic-option1" && bloodEosinophilCount === "bec-option1") {
            var textContainer = document.querySelector(".card-content-item");
            textContainer.innerHTML = outcome1;
        }
        if (allergicStatus === "allergic-option1" && bloodEosinophilCount === "bec-option2") {
            var textContainer = document.querySelector(".card-content-item");
            textContainer.innerHTML = outcome2;
        }
        if (allergicStatus === "allergic-option1" && bloodEosinophilCount === "bec-option3") {
            var textContainer = document.querySelector(".card-content-item");
            textContainer.innerHTML = outcome3;
        }
        if (allergicStatus === "allergic-option1" && bloodEosinophilCount === "bec-option4") {
            var textContainer = document.querySelector(".card-content-item");
            textContainer.innerHTML = outcome4;
        }
        if (allergicStatus === "allergic-option1" && bloodEosinophilCount === "bec-option5") {
            var textContainer = document.querySelector(".card-content-item");
            textContainer.innerHTML = outcome5;
        }
        if (allergicStatus === "allergic-option2" && bloodEosinophilCount === "bec-option1") {
            var textContainer = document.querySelector(".card-content-item");
            textContainer.innerHTML = outcome6;
        }
        if (allergicStatus === "allergic-option2" && bloodEosinophilCount === "bec-option2") {
            var textContainer = document.querySelector(".card-content-item");
            textContainer.innerHTML = outcome7;
        }
        if (allergicStatus === "allergic-option2" && bloodEosinophilCount === "bec-option3") {
            var textContainer = document.querySelector(".card-content-item");
            textContainer.innerHTML = outcome8;
        }
        if (allergicStatus === "allergic-option2" && bloodEosinophilCount === "bec-option4") {
            var textContainer = document.querySelector(".card-content-item");
            textContainer.innerHTML = outcome9;
        }
        if (allergicStatus === "allergic-option2" && bloodEosinophilCount === "bec-option5") {
            var textContainer = document.querySelector(".card-content-item");
            textContainer.innerHTML = outcome10;
        }
        if (allergicStatus === "allergic-option3" && bloodEosinophilCount === "bec-option1") {
            var textContainer = document.querySelector(".card-content-item");
            textContainer.innerHTML = outcome11;
        }
        if (allergicStatus === "allergic-option3" && bloodEosinophilCount === "bec-option2") {
            var textContainer = document.querySelector(".card-content-item");
            textContainer.innerHTML = outcome12;
        }
        if (allergicStatus === "allergic-option3" && bloodEosinophilCount === "bec-option3") {
            var textContainer = document.querySelector(".card-content-item");
            textContainer.innerHTML = outcome13;
        }
        if (allergicStatus === "allergic-option3" && bloodEosinophilCount === "bec-option4") {
            var textContainer = document.querySelector(".card-content-item");
            textContainer.innerHTML = outcome14;
        }
        if (allergicStatus === "allergic-option3" && bloodEosinophilCount === "bec-option5") {
            var textContainer = document.querySelector(".card-content-item");
            textContainer.innerHTML = outcome15;
        }

        setTimeout(function () {
            document.querySelector("#content-end").innerHTML = '<p>Try another patient scenario</p><label for="allergicStatus">Allergic Status</label><select name="allergicStatus" id="allergicStatus"><option value="" disabled selected>Select Status</option><option value="allergic-option1">Allergic to perennial allergen (positive allergy test)</option><option value="allergic-option2">Non-allergic to perennial allergen (negative allergy test)</option><option value="allergic-option3">Unknown</option></select><label for="bloodEosinophilCount">Blood Eosinophil Count</label><select name="bloodEosinophilCount" id="bloodEosinophilCount"><option value="" disabled selected>Select BEC</option><option value="bec-option1">&#60;150</option><option value="bec-option2">150-299</option><option value="bec-option3">300-499</option><option value="bec-option4">&#8805;450</option><option value="bec-option5">Unknown</option></select><button class="re-calculate" id="re-calculate-id">Recalculate</button>';
        }, 3000);
    }
});